

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AZURITY PHARMACEUTICALS, INC.,
Petitioner,

v.

HELSINN HEALTHCARE S.A.,
Patent Owner.

Case IPR2025-00949
Patent No. 10,828,297

JOINT MOTION TO TERMINATE *INTER PARTES* REVIEW

Petitioner Azurity Pharmaceuticals, Inc. (“Azurity”) and Patent Owner Helsinn Healthcare S.A. (“Helsinn”) (collectively, the “Parties”) respectfully request that the Patent Trial and Appeal Board (“Board”) terminate the instant *inter partes* review, IPR2025-00949, pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. § 42.72, as the Parties have reached a settlement agreement.

The Parties are currently involved in five IPRs challenging certain claims of Helsinn’s U.S. Patent Nos. 8,623,826, 9,186,357, 9,943,515, and 10,828,297 (collectively, “Helsinn Patents”):

- IPR2025-00945: U.S. Patent No. 8,623,826
- IPR2025-00946: U.S. Patent No. 9,186,357
- IPR2025-00947: U.S. Patent No. 9,186,357
- IPR2025-00948: U.S. Patent No. 9,943,515
- IPR2025-00949: U.S. Patent No. 10,828,297

The Parties have agreed to resolve all disputes between them relating to the above-identified IPR Proceedings. Pursuant to 37 C.F.R. § 42.74(a), the Parties jointly and respectfully request that the Board terminate the IPR Proceedings.

The instant motion is being concurrently filed herewith in each of the above IPR proceedings.

A true copy of the Settlement Agreement is being filed concurrently with this motion under 37 C.F.R. § 42.74(b). *See* Ex. 2105. The Parties also state that there are no other agreements, oral or written, between the parties made in connection with, or in contemplation of, the termination of this proceeding. The Parties request that the Settlement Agreement be treated as business confidential information under 37 C.F.R. § 42.74(c) and kept separate from the files of the involved patents.

For the foregoing reasons, the Parties respectfully request that the Board grant this Joint Motion and terminate the IPR Proceedings.

Dated: September 15, 2026

Respectfully submitted,

/Eric W. Dittmann/
Eric W. Dittmann
Registration No. 51,188
Counsel for Patent Owner,
Helsinn Healthcare S.A.

/Richard Torczon/
Richard Torczon
Reg. No. 34,448
Counsel for Petitioner,
Azurity Pharmaceuticals, Inc.

CERTIFICATE OF SERVICE

I certify that I caused to be served on the counsel identified below a true and correct copy of the foregoing Joint Motion to Terminate by electronic means on September 15, 2026:

Richard Torczon (rtorczon@wsgr.com)
Jad A. Mills (jmills@wsgr.com)
Michael Rosato (mrosato@wsgr.com)
Wendy Devine (wdevine@wsgr.com)

4877-8318-2285@mail.vault.netdocuments.com

By: /Eric W. Dittmann/
Eric W. Dittmann (Reg. No. 51,188)
Counsel for Patent Owner